UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bevacizumab in metastatic papillary renal cell carcinoma (PRCC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e15158-e15158

2011

Volltextzugriff (PDF)

Antitumor effects of AR-42, a novel histone deacetylase inhibitor, in embryonal carcinoma

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.232-232

2011

Volltextzugriff (PDF)

Phase I study of high-dose interleukin (HD-IL2) and sorafenib in patients with metastatic clear cell renal cell carcinoma (RCC) and melanoma

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.337-337

2011

Volltextzugriff (PDF)

Early outcomes with neoadjuvant high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (HD-MVAC) or gemcitabine and cisplatin (GC) in muscle-invasive urothelial carcinoma of the bladder: A single-institution experience

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.280-280

2011

Volltextzugriff (PDF)

A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.278-278

2011

Volltextzugriff (PDF)

Early outcomes with neoadjuvant high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (HD-MVAC) or gemcitabine and cisplatin (GC) in muscle-invasive urothelial carcinoma of the bladder: A single-institution experience

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e15163-e15163

2011

Volltextzugriff (PDF)

A phase I study of prolonged infusion of triapine in combination with a fixed-dose rate of gemcitabine in patients with advanced solid tumors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.2602-2602

2010

Volltextzugriff (PDF)

Biomodulation of capecitabine by carboplatin and weekly paclitaxel (CCP) in patients with adenocarcinoma of unknown primary (ACUP)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e13022-e13022

2010

Volltextzugriff (PDF)

A comparison study of solid tumor, malignant hematology, and general medicine inpatient services

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13532-e13532

2023

Volltextzugriff (PDF)

Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer

Journal of clinical oncology, 2012-02, Vol.30 (5), p.507-512

2012

Volltextzugriff (PDF)

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

Journal of clinical oncology, 2020-06, Vol.38 (16), p.1797-1806

2020

Volltextzugriff (PDF)

Decade of insights: Bleomycin-induced pneumonitis and use of G-CSF in chemotherapy-treated germ cell testicular tumors and Hodgkin lymphoma—Real-world outcomes from an academic cancer center

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e17013-e17013

2024

Volltextzugriff (PDF)

Impact of systemic therapy (ST) on deferred cytoreductive nephrectomy (CN) perioperative outcomes: A National Surgical Quality Improvement Program (NSQIP) analysis

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.650-650

2023

Volltextzugriff (PDF)

Clinical outcomes of patients with bone-predominant metastatic renal cell carcinoma

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.703-703

2023

Volltextzugriff (PDF)

A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in patients with renal cell carcinoma with brain metastasis previously treated with immune checkpoint blockade

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl)

2024

Volltextzugriff (PDF)

Outcomes of second-line therapies in patients with metastatic de novo small cell prostate cancer (SCPC) and treatment-emergent neuroendocrine prostate cancer (tNEPC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e17022-e17022

2022

Volltextzugriff (PDF)

Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in intermediate and high-risk localized prostate cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e16602-e16602

2019

Volltextzugriff (PDF)

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial

Journal of clinical oncology, 2022-04, Vol.40 (12), p.1312-1322

2022

Volltextzugriff (PDF)

Association of 18 F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4600-4600

2023

Volltextzugriff (PDF)

Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

Journal of clinical oncology, 2021-08, Vol.39 (22), p.2486-2496

2021

Volltextzugriff (PDF)

Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.521-521

2023

Volltextzugriff (PDF)

Extended follow-up report of a randomized phase II trial comparing gemcitabine and cisplatin with or without berzosertib in patients with advanced urothelial carcinoma

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.614-614

2024

Volltextzugriff (PDF)

FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16573-e16573

2023

Volltextzugriff (PDF)

Multi-center, retrospective study of first-line systemic therapy ± immune checkpoint inhibition for metastatic neuroendocrine carcinoma of the urinary tract

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.467-467

2023

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(64)

Sprache

Englisch
(64)

Erscheinungsjahr

n.n

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Bevacizumab in metastatic papillary renal cell carcinoma (PRCC)

Antitumor effects of AR-42, a novel histone deacetylase inhibitor, in embryonal carcinoma

Phase I study of high-dose interleukin (HD-IL2) and sorafenib in patients with metastatic clear cell renal cell carcinoma (RCC) and melanoma

Early outcomes with neoadjuvant high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (HD-MVAC) or gemcitabine and cisplatin (GC) in muscle-invasive urothelial carcinoma of the bladder: A single-institution experience

A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome

Early outcomes with neoadjuvant high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (HD-MVAC) or gemcitabine and cisplatin (GC) in muscle-invasive urothelial carcinoma of the bladder: A single-institution experience

A phase I study of prolonged infusion of triapine in combination with a fixed-dose rate of gemcitabine in patients with advanced solid tumors

Biomodulation of capecitabine by carboplatin and weekly paclitaxel (CCP) in patients with adenocarcinoma of unknown primary (ACUP)

A comparison study of solid tumor, malignant hematology, and general medicine inpatient services

Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

Decade of insights: Bleomycin-induced pneumonitis and use of G-CSF in chemotherapy-treated germ cell testicular tumors and Hodgkin lymphoma—Real-world outcomes from an academic cancer center

Impact of systemic therapy (ST) on deferred cytoreductive nephrectomy (CN) perioperative outcomes: A National Surgical Quality Improvement Program (NSQIP) analysis

Clinical outcomes of patients with bone-predominant metastatic renal cell carcinoma

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in patients with renal cell carcinoma with brain metastasis previously treated with immune checkpoint blockade

Outcomes of second-line therapies in patients with metastatic de novo small cell prostate cancer (SCPC) and treatment-emergent neuroendocrine prostate cancer (tNEPC)

Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in intermediate and high-risk localized prostate cancer

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial

Association of 18 F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies

Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma

Extended follow-up report of a randomized phase II trial comparing gemcitabine and cisplatin with or without berzosertib in patients with advanced urothelial carcinoma

FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes

Multi-center, retrospective study of first-line systemic therapy ± immune checkpoint inhibition for metastatic neuroendocrine carcinoma of the urinary tract

Aktive Filter

Suchergebnisse filtern